Obsidian Therapeutics (NASDAQ:OBX) Rating Increased to Hold at Zacks Research

Obsidian Therapeutics (NASDAQ:OBX) was upgraded by Zacks Research to a “hold” rating in a note issued to investors on Thursday,Zacks.com reports.

Other equities research analysts have also recently issued reports about the stock. TD Cowen initiated coverage on shares of Obsidian Therapeutics in a research report on Thursday. They issued a “buy” rating for the company. Piper Sandler began coverage on shares of Obsidian Therapeutics in a report on Wednesday. They set an “overweight” rating and a $42.00 target price for the company. Two investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $42.00.

Obsidian Therapeutics Price Performance

Shares of OBX stock opened at $27.50 on Thursday. Obsidian Therapeutics has a 52 week low of $23.00 and a 52 week high of $49.97.

Obsidian Therapeutics is a biotechnology company focused on developing engineered cell and gene therapies for cancer and other serious diseases. The company’s approach is designed to improve the safety, control and effectiveness of therapeutic proteins and genetic medicines by enabling their activity to be regulated inside the body.

Obsidian’s technology platform, known as cytoDRiVE, uses small-molecule-controlled genetic systems to modulate the expression or activity of therapeutic proteins.